Boston Scientific Corp (BSX)

Currency in USD
73.77
-0.48(-0.65%)
Real-time Data·
Trading near 52-week Low
BSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
72.6974.50
52 wk Range
72.69109.50
Key Statistics
Prev. Close
74.25
Open
74.17
Day's Range
72.69-74.5
52 wk Range
72.69-109.5
Volume
11.8M
Average Vol. (3m)
12.94M
1-Year Change
-30.402%
Book Value / Share
15.78
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
106.78
Upside
+44.75%
Members' Sentiments
Bearish
Bullish
ProTips
9 analysts have revised their earnings downwards for the upcoming period

Boston Scientific Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Boston Scientific Corp Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corp SWOT Analysis


Navigating Challenges
Delve into BSX's strategy to overcome tariff impacts and the TAVR exit, while leveraging its robust R&D capabilities to drive future innovations
Analyst Optimism
With a consensus recommendation of 1.36, analysts project significant margin expansion and a weighted average market growth rate of 8.5% for 2025
Strategic Acquisitions
Explore BSX's expansion into high-growth areas like renal denervation and neuromodulation through strategic acquisitions of SoniVie and Axonics
Market Dominance
Boston Scientific's impressive 21.44% revenue growth and 20% organic growth highlight its strong market position and effective growth strategies
Read full SWOT analysis

Boston Scientific Corp Earnings Call Summary for Q4/2025

  • Boston Scientific reported Q4 2025 adjusted EPS of $0.80 (beating $0.78 forecast) and revenue of $5.286 billion (up 15.9% YoY), despite an 8.55% stock decline in pre-market trading.
  • Full-year 2025 revenue reached $20.074 billion (up 19.9% YoY), with free cash flow increasing 38% to $3.659 billion and adjusted operating margin expanding by 100 basis points to 28%.
  • The electrophysiology segment grew 35% in Q4, with executives highlighting continued market share gains and successful strategic acquisitions including Valencia Technologies and Penumbra.
  • Management provided optimistic 2026 guidance, projecting 10-11% organic revenue growth and adjusted EPS of $3.43-$3.49 (12-14% growth), with long-term sales growth exceeding 10% annually through 2028.
Last Updated: 02/04/2026, 09:16 AM
Read Full Transcript

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
38.0x29.4x−0.5x
PEG Ratio
0.69−0.560.00
Price / Book
4.7x4.3x2.6x
Price / LTM Sales
5.5x3.9x3.3x
Upside (Analyst Target)
41.4%16.4%44.3%
Fair Value Upside
Unlock8.1%4.9%Unlock

Analyst Ratings

34 Buy
0 Hold
0 Sell
Ratings:
34 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 106.78
(+44.75% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Buy96.00+30.15%-MaintainFeb 06, 2026
Bernstein SocGen Group
Buy112.00+51.84%130.00MaintainFeb 06, 2026
UBS
Buy120.00+62.69%140.00MaintainFeb 05, 2026
JPMorgan
Buy100.00+35.57%135.00MaintainFeb 05, 2026
RBC Capital
Buy115.00+55.91%130.00MaintainFeb 05, 2026

Earnings

Latest Release
Feb 04, 2026
EPS / Forecast
0.80 / 0.78
Revenue / Forecast
5.29B / 5.28B
EPS Revisions
Last 90 days

BSX Income Statement

People Also Watch

822.34
GEV
+3.99%
609.60
SNDK
+12.55%
324.21
TER
+6.34%
277.30
WDC
+5.61%
191.13
NVDA
+1.38%

FAQ

What Is the Boston Scientific (BSX) Stock Price Today?

The Boston Scientific stock price today is 73.77

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 109.09B.

What Is Boston Scientific's Earnings Per Share (TTM)?

The Boston Scientific EPS (TTM) is 1.96.

When Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on Apr 29, 2026.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Boston Scientific Stock Split?

Boston Scientific has split 2 times.

How Many Employees Does Boston Scientific Have?

Boston Scientific has 53000 employees.

What is the current trading status of Boston Scientific (BSX)?

As of Feb 12, 2026, Boston Scientific (BSX) is trading at a price of 73.77, with a previous close of 74.25. The stock has fluctuated within a day range of 72.69 to 74.50, while its 52-week range spans from 72.69 to 109.50.

What Is Boston Scientific (BSX) Price Target According to Analysts?

The average 12-month price target for Boston Scientific is USD106.78, with a high estimate of USD130 and a low estimate of USD90. 34 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.75% Upside potential.

What Is the BSX Premarket Price?

BSX's last pre-market stock price is 74.17. The pre-market share volume is 12,410.00, and the stock has decreased by -0.08, or -0.11%.

What Is the BSX After Hours Price?

BSX's last after hours stock price is 74.60, the stock has decreased by 0.33, or 0.44%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.